News by community

20.10.2017 Abionic Announces FDA Registration for World’s Most Rapid Allergy Test and abioSCOPE® Diagnostic Testing Platform

  • Test detects sensitization to four common respiratory allergens in United States.
  • Scheduled to be commercially available in the US in 2018
  • October 20, 2017 01:00 AM Eastern Daylight Time

 

LAUSANNE, Switzerland–(BUSINESS WIRE)–Abionic SA, a developer of disrupter nanotechnology based rapid diagnostic solutions, announced today that its rapid allergy test, IVD CAPSULE Aeroallergens, and the easy to use testing platform, abioSCOPE® have been registered in the United States by the Food and Drug Administration (FDA). Abionic intends to commence commercialization of IVD CAPSULE Aeroallergens in this market in 2018.

Press release available here

 

back